Itron Analyst Price Targets - Benzinga

SPY769.60 QQQ724.33 BTC/USD82,186.20+0.07%DIA515.63 GLD381.00 TLT80.26

Itron Inc

ITRINASDAQ

Trade with Public

Trade with Public

$84.77

0.350.41%

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Connect With Us

About Benzinga

Market Resources

Advanced Stock Screener Tools
Options Trading Chain Analysis
Comprehensive Earnings Calendar
Dividend Investor Calendar and Alerts
Economic Calendar and Market Events
IPO Calendar and New Listings
Market Outlook and Analysis
Wall Street Analyst Ratings and Targets

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

Itron Analyst Price Targets - Benzinga

Itron Analyst Price Targets

Wall Street analyst price targets and consensus rating for Itron (ITRI).

Price Target Range — 12 Quarters

Analyst Consensus — 15 Analysts

11Buy

4Hold

Consensus RatingBuy# Analysts15Avg. Consensus PT$126Upside to Avg. PT+48.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jul 29, 2026	Needham	Sean Milligan	PT Raise	Buy	$116→$128
May 20, 2026	Stephens & Co.	Tommy Moll	Maintained	Overweight	$130
Apr 29, 2026	TD Cowen	Jeff Osborne	PT Cut	Buy	$145→$130
Apr 16, 2026	JP Morgan	Mark Strouse	PT Cut	Overweight	$133→$113
Apr 16, 2026	Oppenheimer	Noah Kaye	PT Raise	Outperform	$133→$135
Mar 6, 2026	Needham	Sean Milligan	Initiate	Buy	$124
Feb 18, 2026	Oppenheimer	Noah Kaye	PT Raise	Outperform	$125→$133
Feb 18, 2026	Baird	Ben Kallo	Upgrade	Neutral→Outperform	$118→$128
Feb 17, 2026	Guggenheim	Joseph Osha	Downgrade	Buy→Neutral	—
Feb 13, 2026	Guggenheim	Joseph Osha	Downgrade	Buy→Neutral	—
Jan 27, 2026	Oppenheimer	Noah Kaye	PT Cut	Outperform	$145→$125
Jan 5, 2026	Johnson Rice	Martin Malloy	Upgrade	Accumulate→Buy	$130
Nov 4, 2025	Argus Research	John Eade	Downgrade	Buy→Hold	—
Oct 31, 2025	Baird	Ben Kallo	Downgrade	Outperform→Neutral	$137→$118
Oct 16, 2025	JP Morgan	Mark Strouse	PT Raise	Overweight	$145→$155
Oct 7, 2025	Stephens & Co.	Tommy Moll	Maintained	Equal-Weight	$130
Jul 31, 2025	JP Morgan	Mark Strouse	Upgrade	Neutral→Overweight	$128→$145
Jul 22, 2025	Roth Capital	Chip Moore	PT Raise	Buy	$130→$150
Jul 22, 2025	JP Morgan	Mark Strouse	PT Raise	Neutral	$118→$128
Jul 14, 2025	Guggenheim	Joseph Osha	PT Raise	Buy	$133→$155

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Needham Maintains Buy on Itron, Raises Price Target to $128

Needham analyst Sean Milligan maintains Itron (NASDAQ:ITRI) with a Buy and raises the price target from $116 to $128.

Benzinga Newsdesk

PRO
Stephens & Co. Reiterates Overweight on Itron, Maintains $130 Price Target

Stephens & Co. analyst Tommy Moll reiterates Itron (NASDAQ:ITRI) with a Overweight and maintains $130 price target.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Itron, Lowers Price Target to $130

TD Cowen analyst Jeff Osborne maintains Itron (NASDAQ:ITRI) with a Buy and lowers the price target from $145 to $130.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Itron, Lowers Price Target to $113

JP Morgan analyst Mark Strouse maintains Itron (NASDAQ:ITRI) with a Overweight and lowers the price target from $133 to $113.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Itron, Raises Price Target to $135

Oppenheimer analyst Noah Kaye maintains Itron (NASDAQ:ITRI) with a Outperform and raises the price target from $133 to $135.

Benzinga Newsdesk

This Regeneron Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Top Wall Street analysts changed outlook on top names. For all changes, including upgrades/downgrades, see analyst ratings page. What they think of REGN.

Avi Kapoor